Novo Nordisk says experimental drug amycretin show 13% weight loss in trial 

Reuters was first to report on the early trial data for Novo Nordisk’s highly anticipated experimental drug amycretin which showed […] The post Novo Nordisk says experimental drug amycretin show 13% weight loss in trial  appeared first on Reuters News Agency.

Aug 9, 2024 - 15:36
Novo Nordisk says experimental drug amycretin show 13% weight loss in trial 

Reuters was first to report on the early trial data for Novo Nordisk’s highly anticipated experimental drug amycretin which showed that participants had a weight loss of 13.1% after 12 weeks, prompting the company’s shares to rise to record highs and placing it above Tesla by market valuation. 

The post Novo Nordisk says experimental drug amycretin show 13% weight loss in trial  appeared first on Reuters News Agency.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow